Γ
Content Highlights || Full Agenda
Lunch & Learn

12:15 PM

-

1:00 PM

Planetary Health

FoodTech Investing: Lessons Learned and the Road Ahead

The FoodTech sector has moved beyond its first wave of hype into a period of recalibration. Investors and founders alike are reassessing assumptions around cost, scale, and market adoption. In this closed-door luncheon, leading investors and industry operators will share hard-earned lessons from the past cycle and explore how those insights are shaping future investment strategies. From platform bets to capital-efficient models, the discussion will focus on what it takes to build durable FoodTech companies in today’s environment. Expect a candid focused on strategic clarity and actionable insight.

Lunch & Learn

12:15 PM

-

1:00 PM

Planetary Health

FoodTech Investing: Lessons Learned and the Road Ahead

The FoodTech sector has moved beyond its first wave of hype into a period of recalibration. Investors and founders alike are reassessing assumptions around cost, scale, and market adoption. In this closed-door luncheon, leading investors and industry operators will share hard-earned lessons from the past cycle and explore how those insights are shaping future investment strategies. From platform bets to capital-efficient models, the discussion will focus on what it takes to build durable FoodTech companies in today’s environment. Expect a candid focused on strategic clarity and actionable insight.

SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.

The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.

Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.

“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”

Eric Schmidt

Former CEO

"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."

Celestine Schnugg

Founder

"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."

Surge Biswas

Founder

"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."

Jacob Glanville

Founder & CEO

"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."

Bill Tai

Co-founder

"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."

Luis Cascao-Pereira

Head of Digital Biology

"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."

Ola Wlodek

CEO

Who’s Coming to SynBioBeta?

And the BD and R&D Leads
That Will Be Your Customers and Partners: